Plant-based biopharma firm iBio licenses novel antibody targeting regulatory T cells

Anti-CD25 antibodies have emerged as one of the most promising next-generation cancer therapeutics, says US plant-based manufacturer of therapeutics and vaccines, iBio, as it enters the field.